CITADEL ADVISORS LLC 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 4:30 pm Sale | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | CITADEL ADVISORS LLC | 6,660,717 3.800% | -2,234,718 (-25.12%) | Filing |
| 2020-06-10 5:07 pm Purchase | 2020-06-01 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | CITADEL ADVISORS LLC | 8,895,435 5.000% | 8,895,435 (New Position) | Filing |